http://www.oteurope.com/ophthalmologytimeseurope ophthalmology news, features, events and interviews in cataract, refractive, glaucoma, retina and much more. 2010-03-11T15:22:10Z http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Lebers-congenital-amaurosis-sufferers-could-benefi/ArticleStandard/Article/detail/660348?ref=25 Last year a human trial involving administering gene therapy to Leber's congenital amaurosis (LCA) patients produced improvements in 12 children and young adults. The same researchers then conducted an animal study that found that a second injection into the previously untreated eye, was safe and effective with no signs of interference from immune reactions from the earlier injection. 2010-03-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/112010/660348null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/World-Glaucoma-Day/ArticleStandard/Article/detail/660356?ref=25 Glaucoma remains the world's leading cause of irreversible blindness, but 50% of people who have this devastating disease don't know it,” said Dr Clive Midgal, president of the European Glaucoma Society. 2010-03-10T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/112010/660356null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Research-set-to-change-how-we-think-about-glaucoma/ArticleStandard/Article/detail/660355?ref=25 New research is emerging from the Vanderbilt Eye Institute that indicates the first sign of injury in glaucoma occurs in the brain. 2010-03-10T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/112010/660355null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/116th-SFO-Congress/ArticleStandard/Article/detail/660347?ref=25 The Congress of the French Ophthalmology Society, SFO, will take place at the Palais des Congres, 2 place de la Porte Maillot, Paris, France, 8-11 May 2010. 2010-03-10T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/112010/660347null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/NicOx-partners-with-Bausch-amp-Lomb-for-its-candid/ArticleStandard/Article/detail/659735?ref=25 A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116. 2010-03-03T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/102010/659735null HTML http://www.oteurope.com/ophthalmologytimeseurope/The-Crystalens-HD/ArticleStandard/Article/detail/660501?ref=25 Reported highlights from sessions held during the 2009 XXVII ESCRS Congress in Barcelona, Spain. 2010-03-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/112010/660501null PDF http://www.oteurope.com/ophthalmologytimeseurope/Patient-centred-research-provides-a-better-underst/ArticleStandard/Article/detail/659470?ref=25 Sponsored Feature. Xalatan® is to become available across Europe in a newly designed bottle. So what does that mean and what lies behind that decision? 2010-03-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/102010/659470null PDF http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Anti-VEGF-for-AMD-a-top-advancement/ArticleStandard/Article/detail/657452?ref=25 San Francisco?Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advancement in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December. 2010-02-28T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657452null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Wet-AMD-drug-enters-Phase-I-trial/ArticleStandard/Article/detail/657449?ref=25 Palomid 529 (P529) is to enter its Phase I trial in patients with AMD. A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients with Advanced Neovascular Age-Related Macular Degeneration will according to Paloma Pharmaceuticals, be a dose-ranging study for safety but will also have an objective measure for efficacy. 2010-02-27T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657449null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Ranibizumab-for-retinal-angiomatous-proliferation-/ArticleStandard/Article/detail/657447?ref=25 Eye advance online publication 12 February 2010; doi: 10.1038/eye.2010.9 2010-02-26T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657447null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Use-of-heavy-Trypan-blue-in-macular-hole-surgery/ArticleStandard/Article/detail/657446?ref=25 Eye advance online publication 12 February 2010; doi: 10.1038/eye.2010.3 2010-02-25T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657446null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Glaucoma-medications-associated-with-lower-mortali/ArticleStandard/Article/detail/657450?ref=25 Researchers in the journal, Archives of Ophthalmology have indicated that results from a 4-year study of more than 21,000 Americans point to an association between glaucoma medications and a lower death rate. 2010-02-24T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657450null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/VEGF-Trap-Eye-shows-positive-results-in-a-phase-2-/ArticleStandard/Article/detail/657905?ref=25 VEGF Trap-Eye, the fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PIGF), has shown positive results in a Phase 2 study in patients with diabetic macular oedema (DME. 2010-02-24T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657905null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/EMA-approval-sought-for-non-infectious-uveitis-dru/ArticleStandard/Article/detail/657461?ref=25 LUVENIQ (LX211; oral voclosporin) has been filed for approval by the European Medicines Agency (EMA) and the US's Food and Drug Administration by Lux Biosciences. The drug is aimed at treatment of non-infectious uveitis for the intermediate or posterior segments of the eye. 2010-02-18T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657461null HTML http://www.oteurope.com/ophthalmologytimeseurope/Coherent-Sells-Over-7500-Excimer-Lasers-for-Refrac/ArticleStandard/Article/detail/653961?ref=25 Coherent is unique amongst laser manufacturers in the breadth of our excimer laser product portfolio and the depth of our experience in building products for both Laser-Assisted In Situ Keratomileusis (LASIK) and other refractive techniques. 2010-02-17T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/052010/653961null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Potential-of-microplsamin-to-improve-the-treatment/ArticleStandard/Article/detail/657463?ref=25 A paper entitled A Placebo-Controlled Trial of Microplasmin Intravitreous Injection to Facilitate Posterior Vitreous Detachment Before Vitrectomy has been published online ahead of print in Ophthalmology. 2010-02-17T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657463null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Pfizer-CEO-receives-award/ArticleStandard/Article/detail/655840?ref=25 Pfizer's CEO, Jeffrey Kindler has received the 2010 Catalyst Award, the Glaucoma Research Foundation's highest honour, acknowledging his role in sustaining innovative research and education. 2010-02-16T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/072010/655840null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/International-oculoplastic-reconstruction-and-trau/ArticleStandard/Article/detail/655837?ref=25 An international course on ophthalmic and oculoplastic reconstruction and trauma surgery will be taking place in Vienna from April 15-17 at the Vienna General Hospital/Neurosurgical Laboratory. 2010-02-15T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/072010/655837null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Innovative-glaucoma-research-award/ArticleStandard/Article/detail/655841?ref=25 The Glaucoma Research Foundation (GRF) awarded the 2010 Shaffer Prize for Innovative Glaucoma Research to Kate Keller, PhD. Dr Keller is Research Assistant Professor, Department of Ophthalmology at Casey Eye Institute in Portland, Oregon. 2010-02-13T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/072010/655841null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/iPhot-receives-a-940K128-grant/ArticleStandard/Article/detail/656658?ref=25 iPhot, the collaborative project for continuing the development of Imagine Eyes' rtx1 Adaptive Optics Retinal Camera has received a 940K€ (approximately $US1.35M) grant from France's National Research Agency (ANR) TecSan programme. 2010-02-13T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/072010/656658null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Gene-genie-for-AMD-and-RP/ArticleStandard/Article/detail/655838?ref=25 Retinitis pigmentosa and AMD may be the beneficiaries of a new tool for gene therapy that significantly increases gene delivery to cells in the retina. 2010-02-12T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/072010/655838null HTML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+news/Eyes-on-Oman/ArticleStandard/Article/detail/656636?ref=25 More than 150 participants from 27 countries attended this year's SCHWIND User Meeting in Muscat, Oman. 2010-02-12T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/072010/656636null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Gene-associated-with-long-sightedness-discovered-d/ArticleStandard/Article/detail/655839?ref=25 Australia's Centre for Eye Research has discovered a hepatocyte growth factor (HGF) gene, which it hopes will provide important insights into biological mechanisms involved in ocular development. 2010-02-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/072010/655839null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Changes-at-Hoya/ArticleStandard/Article/detail/656657?ref=25 Hans Werquin will become CEO of Hoya Vision Care Europe from the beginning of April 2010. He will report to Gerald Bottero, who has been leading the European branch for the past five years. Bottero remains CEO of Hoya Vision Care globally. 2010-02-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/072010/656657null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Eye-spy-an-art-forgery/ArticleStandard/Article/detail/656634?ref=25 Optical coherence tomography (OCT) is being put to a secondary use by scientists in Poland 2010-02-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/072010/656634null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Alcons-independent-directors-fight-back-Novartis-c/ArticleStandard/Article/detail/655337?ref=25 Novartis plans to assume complete control over Alcon Laboratories Inc. in a two-step process that some analysts and some members of Alcon?s board of directors are challenging for its fairness under Swiss and US merger laws. 2010-02-10T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/062010/655337null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Kaiser-study-results-on-ranibizumab-and-bevacizuma/ArticleStandard/Article/detail/655385?ref=25 A Kaiser Permanents Southern California study published in this month?s Ophthalmology, the journal of the American Academy of Ophthalmology, compares ranibizumab (Lucentis) and bevacizumab (Avastin) and found them to be equally effective in halting vision loss. 2010-02-04T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/062010/655385null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Alcon-acquires-Sirion-products/ArticleStandard/Article/detail/653120?ref=25 Alcon is to buy the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc Durezol, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers). 2010-01-27T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042010/653120null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Eye-test-could-help-detect-signs-of-Alzheimers/ArticleStandard/Article/detail/653117?ref=25 Research published in the journal Cell Death and Disease by University College of London scientists indicates that a simple eye test may, in future, be able to detect Alzheimer's, amongst other diseases. 2010-01-27T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042010/653117null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Pfizer-CEO-gets-glaucoma-award/ArticleStandard/Article/detail/653121?ref=25 The Glaucoma Research Foundation?s highest honour, the Catalyst Award, has been given to Jeffrey B. Kindler, chief executive officer and chairman of the Board of Pfizer Inc. The award recognizes outstanding accomplishments in research and education in support of those affected by glaucoma. 2010-01-27T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042010/653121null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Stem-cell-therapy-to-treat-LSCD/ArticleStandard/Article/detail/653116?ref=25 Successful limbal stem cell deficiency (LSCD) treatment in eight patients using their own stem cells without immunity suppression has been reported by scientists at the North East England Stem Cell Institute (NESCI). 2010-01-27T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042010/653116null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Alcon-acquires-Optonol/ArticleStandard/Article/detail/653122?ref=25 Alcon has entered into the surgical glaucoma market by acquiring Optonol, a manufacturer and marketer of novel minature surgical implants used to reduce IOP. 2010-01-27T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042010/653122null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Presbia-strengthens-its-surgical-team/ArticleStandard/Article/detail/653119?ref=25 Presbia , which develops and markets a surgical solution for presbyopia has appointed ophthalmic surgeons Dr Jorge L. Alio of Madrid, Spain (an OTEurope editorial advisory board member) and Dr Kerry K. Assil of California, have agreed to serve on its Medical Advisory Board. 2010-01-27T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042010/653119null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Alcon-spurns-Novartis-proposals-as-grossly-inadequ/ArticleStandard/Article/detail/653109?ref=25 Alcon's formal response to Novartis' s proposal to acquire the minority publicly traded shares of Alcon. In a letter to the CEO of Novartis the Alcon Committee said that the terms proposed were “grossly inadequate.” 2010-01-27T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042010/653109null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Zeiss-to-get-new-CEO/ArticleStandard/Article/detail/653115?ref=25 Carl Zeiss's current CEO, Dr Michael Kaschke, has resigned his position on the company?s Management Board. 2010-01-27T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042010/653115null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Controversies-in-ophthalmology/ArticleStandard/Article/detail/651114?ref=25 The full scientific programme for the March Congress is now available. 2010-01-13T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032010/651114null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/New-study-demonstrates-potential-for-improving-gla/ArticleStandard/Article/detail/651124?ref=25 Research claims that imaging devices can effectively support ophthalmologists with glaucoma diagnosis 2010-01-13T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032010/651124null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+Clinicals/First-ever-sham-controlled-study-of-radiation-ther/ArticleStandard/Article/detail/651120?ref=25 )? Oraya Therapeutics, Inc., announced today that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD). The groundbreaking clinical trial is being conducted at seven European sites, and will include a minimum of 150 patients, with approximately one third of those receiving a sham exposure and the remainder receiving radiation dosing of either 16 or 24 Gray (GY). 2010-01-13T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032010/651120null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Can-micronutrients-help-DR/ArticleStandard/Article/detail/651123?ref=25 Researchers in The Netherlands have concluded that dietary intake or plasma levels of vitamins C and E and magnesium do not seem to be associated with diabetic retinopathy. 2010-01-13T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032010/651123null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/BluePeak-swirls-online-to-new-microsite/ArticleStandard/Article/detail/651112?ref=25 Heidelberg Engineering has launched an informative microsite about BluePeak blue laser autofluorescence. 2010-01-13T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032010/651112null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+features/A-randomised-trial-of-bevacizumab-and-reduced-ligh/ArticleStandard/Article/detail/651113?ref=25 Combination bevacizumab and 25?J/cm2 or 12?J/cm2 PDT significantly reduced the number of bevacizumab treatments required over six months. This study aimed at examining number of treatments, but not visual acuities. However, visual acuities responded favourably in all three groups. 2010-01-13T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032010/651113null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Local-anaesthesia-for-cataract-surgery/ArticleStandard/Article/detail/650054?ref=25 A comparative evaluation of local anaesthesia for cataract surgery, published in The Journal of Cataract & Refractive Surgery says that randomized clinical trials are needed to facilitate statistical methods of metaanalysis to establish convincingly the overall benefits and efficacy of the various local anesthesia procedures in cataract surgery. 2010-01-06T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/022010/650054null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Current-approach-in-diagnosis-and-management-of-an/ArticleStandard/Article/detail/650051?ref=25 In this article R.V. Agrawal et al., assist ophthalmologists in accurately diagnosing anterior uveitis. 2010-01-06T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/022010/650051null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Leader-of-national-blind-charity-honoured/ArticleStandard/Article/detail/650052?ref=25 The President of the Macular Disease Society (MDS), Gwyneth Dickinson, has been awarded the MBE in the UK's New Year's Honours. Mrs Dickinson, a former nurse, is honoured for her voluntary work as a trustee, Chairman and now President of the Society. 2010-01-06T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/022010/650052null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Novartis-announces-option-exercise-and-merger-prop/ArticleStandard/Article/detail/650055?ref=25 Novartis is to exercise its option to purchase the remaining shares in Alcon, Inc., owned by Nestle S.A. at a weighted average price of US$180 per share in cash following the agreement between Nestle and Novartis in April 2008. 2010-01-06T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/022010/650055null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Steroid-injections-may-slow-proliferative-diabetic/ArticleStandard/Article/detail/650057?ref=25 A recent study, published in the Archives of Ophthalmology found that injections of a corticosteroid, triamcinolone directly into the eye may slow progression of proliferative diabetic retinopathy (DR). 2010-01-06T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/022010/650057null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Resolution-of-macular-oedema-in-Coats-disease-with/ArticleStandard/Article/detail/650056?ref=25 A 13-year-old boy was referred because of visual deterioration in his right eye. The visual acuity was two metres of counting fingers. Indirect ophthalmoscopy and biomicroscopy revealed exudative macular oedema as well as tumour-like telangiectatic vessels and exudation in temporal periphery. 2010-01-06T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/022010/650056null HTML http://www.oteurope.com/ophthalmologytimeseurope/IOL+articles/Bausch-amp-Lomb-Introduces-the-Crystalens-Aspheric/ArticleStandard/Article/detail/650092?ref=25 Crystalens AO is the first aberration-free accommodating IOL 2010-01-05T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/022010/650092null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/Diabetic-retinopathy-A-growing-concern-in-an-agein/ArticleStandard/Article/detail/657489?ref=25 Diabetic retinopathy is a rising threat as the diabetic population increases 2010-01-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657489null XML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/Proper-supplement-use-advised-for-people-with-or-a/ArticleStandard/Article/detail/657493?ref=25 The Ophthalmology Times Group talked to an optometrist practice about their experience with ocular nutraceuticals 2010-01-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657493null XML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/Using-imaging-to-monitor-retinal-tissue-response/ArticleStandard/Article/detail/657492?ref=25 Retinal tissue response after PASCAL laser photocoagulation 2010-01-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657492null XML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/Eyes-front/ArticleStandard/Article/detail/657487?ref=25 2009 heralded more interesting developments for ophthalmology. OTEurope asked some of Europe's leading key opinion leaders for their thoughts on the news and developments that generated most excitement or had most significance in the Cataract & Refractive sector 2010-01-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657487null XML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+features/Glaucoma-management-with-endoscopic-cycloPhotocoag/ArticleStandard/Article/detail/657488?ref=25 The Endoscopic CycloPhotocoagulation (ECP) technique provides an option for surgical glaucoma management, addressing ciliary aqueous production without the deeply destructive effects of classic ablative procedures. Dr Liegner explains 2010-01-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657488null XML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/HEATAM-Meetings-12-and-3/ArticleStandard/Article/detail/657495?ref=25 Professor David Wong reports on the third Heavy Tamponade meeting in Amsterdam and explains the background from the first and second events 2010-01-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657495null XML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/Let-there-be-light/ArticleStandard/Article/detail/657491?ref=25 Dr Bobby Qureshi, the first surgeon in the UK to carry out implant surgery using light adjustable lenses, he talks to OTEurope about the procedure 2010-01-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657491null XML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+features/Improved-tools-allow-better-care/ArticleStandard/Article/detail/657490?ref=25 Progress in glaucoma followed a slow, steady course in 2009, according to specialists 2010-01-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657490null XML http://www.oteurope.com/ophthalmologytimeseurope/As-good-staff-are-so-hard-to-find/ArticleStandard/Article/detail/657494?ref=25 Ensure that your human capital knows how to win loyal patients and can help your practice grow 2010-01-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082010/657494null XML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Alcon-acquires-Optonol/ArticleStandard/Article/detail/648245?ref=25 Alcon acquires Optinol and enters glaucoma surgical market. 2009-12-14T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/512009/648245null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Novel-scleral-lens-proves-cost-effective/ArticleStandard/Article/detail/646970?ref=25 In the December issue of the American Journal of Ophthalmology Brandeis University researchers published a paper about the highly precise scleral lens, to treat severe cornea or ocular surface disease, the Boston Ocular Surface Prosthesis (BOS-P). 2009-12-09T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/646970null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Producing-corneas-for-human-transplant/ArticleStandard/Article/detail/646969?ref=25 Northeastern University engineering professor Jeffrey Ruberti and his research colleagues are breaking new ground in the technique known as "hybrid tissue engineering" by attempting to combine cow tissue with human tissue to produce corneas for human transplant. 2009-12-09T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/646969null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/IVB-combined-with-panretinal-photocoagulation-in-t/ArticleStandard/Article/detail/646971?ref=25 Findings published in the European Journal of Ophthalmology have found that intravitreal bevacizumab (IVB) combined with panretinal photocoagulation in patients with open angle neovascular glaucoma (NVG) can reduce iris and angle neovascularization and temporarily inhibit further PAS formation. 2009-12-09T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/646971null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/60-years-of-pioneering-IOL-innovation/ArticleStandard/Article/detail/646968?ref=25 Rayner Intraocular Lens Limited, has marked a milestone with a celebration to honour the 60th anniversary of the implantation of the first intraocular lens (IOL) in a patient. The late Sir Harold Ridley implanted the first IOL on 29 November 1949 at St. Thomas Hospital in London. Due to the controversial nature of the surgery, this first surgery was conducted in almost total secrecy. 2009-12-09T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/646968null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Research-grant-for-Inherited-retinal-disease-care/ArticleStandard/Article/detail/646977?ref=25 Fight for Sight has announced £500,000 funding for a new research programme to develop an optimal model of care services for patients with inherited retinal diseases. The five-year programme will be led by Professor Graeme Black, Director of the National Institute for Health Research Manchester Biomedical Research Centre, supported by Professor Tony Moore of Moorfields Eye Hospital and Miss Susie Downes of Oxford Eye Hospital. 2009-12-09T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/646977null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Light-adjustable-lens-surgery-comes-to-the-UK/ArticleStandard/Article/detail/646973?ref=25 Ophthalmic surgeon Bobby Qureshi is the first in the UK to implant light-adjustable lenses (LALs), which have the capacity to be altered after surgery to provide the best vision for each individual eye without glasses. 2009-12-09T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/646973null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Scottish-Medicines-Consortium-accepts-first-preser/ArticleStandard/Article/detail/647247?ref=25 The Scottish Medicines Consortium (SMC) has announced that Saflutan (tafluprost) has been accepted for restricted use within NHS Scotland for the reduction of elevated intraocular pressure (IOP) in open angle glaucoma and ocular hypertension 2009-12-08T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647247null HTML http://www.oteurope.com/ophthalmologytimeseurope/New-MISS-technique/ArticleStandard/Article/detail/647701?ref=25 Transconjunctival Muscle Suturing is a new technique that decreases the size of opening by approximately one third. 2009-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647701null XML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+features/Pen-like-tonometer-desgined-to-be-patient-friendly/ArticleStandard/Article/detail/647697?ref=25 A proprietary tonometer has been found to be compatible with the Goldmann tonometer in several clinical trials. 2009-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647697null XML http://www.oteurope.com/ophthalmologytimeseurope/Cell-loss-plateaus-eariler-in-DSAtildebrvbarK-than/ArticleStandard/Article/detail/647696?ref=25 Data suggest endothelial stability with Descemet's stripping automated endothelial keratoplasty but is longer-term follow-up needed? 2009-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647696null XML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/Laser-enables-fast-ablation-increases-safety-effic/ArticleStandard/Article/detail/647695?ref=25 A superior refractive corneal correction can be achieved by the preservation of corneal tissue as well as optimization of ablation profiles that are better adapted to human sight. 2009-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647695null XML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/Femtosecond-laser-Beyond-capsultomy/ArticleStandard/Article/detail/647699?ref=25 Several manufacturers are developing femtosecond laser technology as a tool for multiple applications in cataract surgery. Three surgeons, who presented at this year's ESCRS Congress look at its uses and results. 2009-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647699null XML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+features/SFI-allows-integration-of-structural-functional-da/ArticleStandard/Article/detail/647693?ref=25 New model produces results comparable with current glaucoma assessment methods 2009-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647693null XML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/Which-IOL-to-choose/ArticleStandard/Article/detail/647692?ref=25 A doctor's perspective on what influences IOL lens design. 2009-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647692null XML http://www.oteurope.com/ophthalmologytimeseurope/The-MADI-plication-mdash-a-revised-technique/ArticleStandard/Article/detail/647691?ref=25 A comparison study of patients who underwent minimally invasive strabismus surgery (MISS) with a total dissection of the plicated part of the rectus muscle and those who had MISS where only a marginal dissection was performed. 2009-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647691null XML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/DME-responds-to-ranibizumab/ArticleStandard/Article/detail/647694?ref=25 Diabetic macular oedema responds to treatment with ranibizumab according to the results of the RESOLVE study. 2009-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647694null XML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/One-piece-design-provides-additional-benefit-to-an/ArticleStandard/Article/detail/647700?ref=25 A new Tecnis intraocular lens harnesses the ease of implantation of a one-piece implant design and combines it with a glistening-free hydrophobic acrylic material for another next generation IOL. 2009-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647700null XML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/The-experience-of-international-surgery-mdash-a-bl/ArticleStandard/Article/detail/647698?ref=25 Performing surgery in unfamiliar surroundings. 2009-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647698null XML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Protecting-retinal-cells-could-save-sight/ArticleStandard/Article/detail/643454?ref=25 A study into the process of retinal cell death could hold the key to stopping a variety of eye diseases that cause blindness, according to a report from a team of researchers from the Yale School of Medicine reported in the journal Investigative Ophthalmology & Visual Science. 2009-11-25T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482009/643454null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Errors-in-the-OR/ArticleStandard/Article/detail/643482?ref=25 Poor communication is leading to a high number of mistakes in ophthalmic surgeries, according to a study published in the November issue of Archives of Surgery. 2009-11-25T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482009/643482null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/CE-mark-awarded/ArticleStandard/Article/detail/643455?ref=25 Oertli?s new surgical platform Faros, has received its CE mark after meeting EU consumer safety, health or environmental requirements. This important step for the platform keeps it on schedule for an expected March 2010 release. 2009-11-25T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482009/643455null HTML http://www.oteurope.com/ophthalmologytimeseurope/Excimer-laser-for-multiple-applications/ArticleStandard/Article/detail/608040?ref=25 The ExciStar XS series from Coherent, Inc. represents a compact, economical excimer laser offering performance and lifetime characteristics. 2009-11-25T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/272009/608040null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Treating-eye-disease-with-stem-cells/ArticleStandard/Article/detail/643453?ref=25 Advanced Cell Technology has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic-stem-cell-derived retinal cells to treat patients with Stargardt?s Macular Dystrophy (SMD). 2009-11-25T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482009/643453null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/First-neovascular-AMD-patients-in-Europe-treated-w/ArticleStandard/Article/detail/643452?ref=25 NeoVista has announced that treatment for neovascular AMD using the company?s VIDON ANV Therapy System has begun in Europe. The new system replaces the current course of eye injections with a surgical vitrectomy and a single dose of beta radiation. 2009-11-25T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482009/643452null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Laser-system-for-treatment-of-glaucoma-gets-Europe/ArticleStandard/Article/detail/640188?ref=25 The IOPtiMate laser-based system, from the Bio-Light Group, used for the non-invasive filtration treatment of glaucoma has received European Patent Office approval. 2009-11-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462009/640188null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/6000-international-doctors-made-the-trip-to-AAO/ArticleStandard/Article/detail/640190?ref=25 2009-11-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462009/640190null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Lumenis-initiates-clinical-study-into-SRT-efficacy/ArticleStandard/Article/detail/640186?ref=25 Lumenis is to undertake a clinical study into the efficacy of selective retina therapy (SRT) in diabetic macular oedema (DME). 2009-11-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462009/640186null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/New-generation-of-diagnostic-ultrasound-system-unv/ArticleStandard/Article/detail/640187?ref=25 Ellex Medical Lasers Ltd. unveiled the latest version of its diagnostic ultrasound system (Eye Cubed) at the recent annual meeting of the American Academy of Ophthalmology. 2009-11-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462009/640187null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Santen-CEO-joins-Glaucoma-Research-Foundation/ArticleStandard/Article/detail/640189?ref=25 Adrienne Graves, CEO of Santen Inc., has been appointed to the Glaucoma Research Foundation?s board of directors. 2009-11-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462009/640189null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/New-retinal-navigation-system-gains-approval/ArticleStandard/Article/detail/640185?ref=25 The NAVILAS laser system, as reported on in the OTE Digest back in May this year ( What is Retinal Navigation? ) has been given FDA approval. 2009-11-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462009/640185null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/Low-hormones-may-havbe-a-role-in-AMD-pathogenesis/ArticleStandard/Article/detail/647680?ref=25 A new hypothesis about the development of AMD points to a role of age-depleted steroidal hormones. An ophthalmologist discusses the evidence supporting this idea. 2009-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647680null XML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/Setting-yourself-up-for-success-in-refractive-surg/ArticleStandard/Article/detail/647684?ref=25 In the second of a two-part article Dr David Tanzer says that in today's US Navy the preferred refractive procedure today is wavefront-guided LASIK with a thin flap made with a femtosecond laser. 2009-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647684null XML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/Phacomorphing-improves-lens-removal-efficiency/ArticleStandard/Article/detail/647687?ref=25 A proprietary phacoemulsification system featuring fluidics control software that allows automatic switching from longitudinal ultrasound to transversal on recognition of occulsion and back again to longitudinal on occlusion break. 2009-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647687null XML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+features/Preservative-free-formulations-of-interest-to-doct/ArticleStandard/Article/detail/647686?ref=25 Participants in a survey showed low awareness that this option was available for patients with glaucoma. 2009-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647686null XML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/New-dual-optic-accommodating-IOL/ArticleStandard/Article/detail/647681?ref=25 An accommodating lens has the potential to provide functional vision at all distances in a seamless continuum and overcome dysphotopsias. 2009-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647681null XML http://www.oteurope.com/ophthalmologytimeseurope/Blue-Laser-Autofluorescence/ArticleStandard/Article/detail/651315?ref=25 The fusion of imaging technology for today and tomorrow to assess your patients' retinal health 2009-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032010/651315null PDF http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/Dispersive-cohesive-OVD-performs-well-during-all-s/ArticleStandard/Article/detail/647690?ref=25 One surgeon's preference for an ophthalmic viscosurgical device of 1.6% sodium hyaluronate was reinforced by a study that found it superior to another OVD during phaco and OVD removal 2009-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647690null XML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/New-Bimanual-Rhexis-technique-for-sub-1-mm-incisio/ArticleStandard/Article/detail/647688?ref=25 A new bimanual capsulorhexis technique, suing a specially developed instrument allowing a tri-dimensional, sub 1mm capsulorhexis with improved maintenance of the anterior chamber. 2009-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647688null XML http://www.oteurope.com/ophthalmologytimeseurope/CatRef+features/EUREQUO---the-idea-and-the-execution/ArticleStandard/Article/detail/647689?ref=25 Professor Mats Lundstrom, chairman of EUREQUO, talks to OTE about the project and its dissemination in Europe. 2009-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647689null XML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+features/Hyperaemia-is-a-common-cause-for-changing-medicati/ArticleStandard/Article/detail/647682?ref=25 Hyperaemia is one of the main reasons why patients with glaucoma do not comply with or persist with their topical therapeutic regimen. 2009-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647682null XML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/Addressing-diabetic-retinopathy-by-treating-underl/ArticleStandard/Article/detail/647683?ref=25 For now, the most effective way to prevent or manage diabetic retinopathy is taking a proactive approach to controlling blood glucose levels and hypertension in patients. 2009-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647683null XML http://www.oteurope.com/ophthalmologytimeseurope/Is-an-MBA-the-right-decision-for-me/ArticleStandard/Article/detail/647685?ref=25 Taking the first step towards analysing your career goals and the return on your investment. 2009-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647685null XML